-
Something wrong with this record ?
Relative inhibitory activities of newly developed diazabicyclooctanes, boronic acid derivatives, and penicillin-based sulfone β-lactamase inhibitors against broad-spectrum AmpC β-lactamases
C. Le Terrier, P. Mlynarcik, M. Sadek, P. Nordmann, L. Poirel
Language English Country United States
Document type Journal Article
Grant support
Université de Fribourg (Universität Freiburg)
National Institute of Virology and Bacteriology (Programme EXCELES, ID Project No. LX22NPO5103) - funded by the European Union - Next Generation EU
NLK
Free Medical Journals
from 1972 to 6 months ago
Freely Accessible Science Journals
from 1995 to 6 months ago
PubMed Central
from 1972 to 1 year ago
Europe PubMed Central
from 1972 to 6 months ago
Open Access Digital Library
from 1972-01-01
Open Access Digital Library
from 1972-01-01
PubMed
39365068
DOI
10.1128/aac.00775-24
Knihovny.cz E-resources
- MeSH
- Acinetobacter baumannii * drug effects enzymology MeSH
- Anti-Bacterial Agents * pharmacology chemistry MeSH
- Azabicyclo Compounds * pharmacology chemistry MeSH
- Bacterial Proteins * antagonists & inhibitors metabolism MeSH
- beta-Lactamases * metabolism MeSH
- Bridged Bicyclo Compounds, Heterocyclic pharmacology chemistry MeSH
- Cyclooctanes MeSH
- beta-Lactamase Inhibitors * pharmacology chemistry MeSH
- Boronic Acids * pharmacology chemistry MeSH
- Lactams MeSH
- Microbial Sensitivity Tests * MeSH
- Penicillins pharmacology chemistry MeSH
- Piperidines MeSH
- Sulfones pharmacology chemistry MeSH
- Publication type
- Journal Article MeSH
The relative inhibitory activities of diazabicyclooctanes (avibactam, relebactam, zidebactam, nacubactam, durlobactam), boronic acid derivatives (vaborbactam, taniborbactam, xeruborbactam), and penicillin-based sulfone derivative enmetazobactam were evaluated against several intrinsic and acquired class C β-lactamases. By contrast to vaborbactam and enmetazobactam, taniborbactam, xeruborbactam, and all diazabicyclooctanes demonstrated effective activities against most AmpC enzymes. Notably, durlobactam exhibited the most pronounced inhibitory effect. Interstingly, the chromosomal AmpC of Acinetobacter baumannii was the least sensitive enzyme to the newly developed β-lactamase inhibitors.
Division of Intensive Care Unit University Hospitals of Geneva Geneva Switzerland
Swiss National Reference Center for Emerging Antibiotic Resistance Fribourg Switzerland
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25003511
- 003
- CZ-PrNML
- 005
- 20250206104402.0
- 007
- ta
- 008
- 250121s2024 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1128/aac.00775-24 $2 doi
- 035 __
- $a (PubMed)39365068
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Le Terrier, Christophe $u Medical and Molecular Microbiology, Faculty of Science and Medicine, University of Fribourg, Fribourg, Switzerland $u Division of Intensive Care Unit, University Hospitals of Geneva, Geneva, Switzerland $1 https://orcid.org/0000000254555576
- 245 10
- $a Relative inhibitory activities of newly developed diazabicyclooctanes, boronic acid derivatives, and penicillin-based sulfone β-lactamase inhibitors against broad-spectrum AmpC β-lactamases / $c C. Le Terrier, P. Mlynarcik, M. Sadek, P. Nordmann, L. Poirel
- 520 9_
- $a The relative inhibitory activities of diazabicyclooctanes (avibactam, relebactam, zidebactam, nacubactam, durlobactam), boronic acid derivatives (vaborbactam, taniborbactam, xeruborbactam), and penicillin-based sulfone derivative enmetazobactam were evaluated against several intrinsic and acquired class C β-lactamases. By contrast to vaborbactam and enmetazobactam, taniborbactam, xeruborbactam, and all diazabicyclooctanes demonstrated effective activities against most AmpC enzymes. Notably, durlobactam exhibited the most pronounced inhibitory effect. Interstingly, the chromosomal AmpC of Acinetobacter baumannii was the least sensitive enzyme to the newly developed β-lactamase inhibitors.
- 650 12
- $a azabicyklické sloučeniny $x farmakologie $x chemie $7 D053961
- 650 12
- $a inhibitory beta-laktamasy $x farmakologie $x chemie $7 D065093
- 650 12
- $a kyseliny boronové $x farmakologie $x chemie $7 D001897
- 650 12
- $a beta-laktamasy $x metabolismus $7 D001618
- 650 12
- $a mikrobiální testy citlivosti $7 D008826
- 650 12
- $a Acinetobacter baumannii $x účinky léků $x enzymologie $7 D040981
- 650 12
- $a antibakteriální látky $x farmakologie $x chemie $7 D000900
- 650 12
- $a bakteriální proteiny $x antagonisté a inhibitory $x metabolismus $7 D001426
- 650 _2
- $a peniciliny $x farmakologie $x chemie $7 D010406
- 650 _2
- $a sulfony $x farmakologie $x chemie $7 D013450
- 650 _2
- $a bicyklické sloučeniny heterocyklické $x farmakologie $x chemie $7 D019086
- 650 _2
- $a laktamy $7 D007769
- 650 _2
- $a piperidiny $7 D010880
- 650 _2
- $a cyklooktany $7 D034242
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Mlynarcik, Patrik $u Medical and Molecular Microbiology, Faculty of Science and Medicine, University of Fribourg, Fribourg, Switzerland $u Department of Microbiology, Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, Czechia $1 https://orcid.org/000000031496775X
- 700 1_
- $a Sadek, Mustafa $u Medical and Molecular Microbiology, Faculty of Science and Medicine, University of Fribourg, Fribourg, Switzerland $u Department of Food Hygiene and Control, Faculty of Veterinary Medicine, South Valley University, Qena, Egypt $1 https://orcid.org/0000000339833862
- 700 1_
- $a Nordmann, Patrice $u Medical and Molecular Microbiology, Faculty of Science and Medicine, University of Fribourg, Fribourg, Switzerland $u Swiss National Reference Center for Emerging Antibiotic Resistance, Fribourg, Switzerland $1 https://orcid.org/0000000213431622
- 700 1_
- $a Poirel, Laurent $u Medical and Molecular Microbiology, Faculty of Science and Medicine, University of Fribourg, Fribourg, Switzerland $u Swiss National Reference Center for Emerging Antibiotic Resistance, Fribourg, Switzerland $1 https://orcid.org/0000000151605286
- 773 0_
- $w MED00009215 $t Antimicrobial agents and chemotherapy $x 1098-6596 $g Roč. 68, č. 11 (2024), s. e0077524
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/39365068 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250121 $b ABA008
- 991 __
- $a 20250206104358 $b ABA008
- 999 __
- $a ok $b bmc $g 2263335 $s 1239518
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 68 $c 11 $d e0077524 $e 20241004 $i 1098-6596 $m Antimicrobial agents and chemotherapy $n Antimicrob Agents Chemother $x MED00009215
- GRA __
- $p Université de Fribourg (Universität Freiburg)
- GRA __
- $p National Institute of Virology and Bacteriology (Programme EXCELES, ID Project No. LX22NPO5103) - funded by the European Union - Next Generation EU
- LZP __
- $a Pubmed-20250121
